Data / Drug companies / Oceanside Pharmaceuticals
Oceanside Pharmaceuticals: 78 products in the FDA NDC directory, labeler code 68682
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Oceanside Pharmaceuticals (labeler code 68682) lists 78 products in the FDA National Drug Code Directory, covering 36 finished drugs by generic name. By type: 78 prescription drugs. Its main marketing category is authorized generics (NDA). The newest product started marketing on June 29, 2026.
The request: Watch Oceanside Pharmaceuticals (FDA labeler code 68682): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68682
- Products in commercial distribution
- 78
- Packages
- 104
- Finished drugs by generic name
- 36
- Prescription products
- 78
- Over the counter products
- 0
- Controlled substance products
- Schedule III 1, Schedule IV 3
- Flagged as original packager
- 78 of 78 products that carry the flag
- Started marketing in the last 12 months
- 3
- Products with a marketing end date set
- 6
- Earliest marketing start
- January 10, 1967
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Authorized generics (NDA) | 50 | 64.1% |
| Generic drugs (ANDA) | 18 | 23.1% |
| New drug applications (NDA) | 10 | 12.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 78 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Diltiazem hydrochloride | 14 | 55 |
| Diltiazem hydrochloride extended-release tablets | 6 | 1 |
| Nifedipine | 5 | 38 |
| Tretinoin | 4 | 28 |
| Enalapril maleate | 4 | 32 |
| Bupropion hydrobromide | 3 | 2 |
| Diazepam | 3 | 51 |
| Pimecrolimus | 3 | 4 |
| Clindamycin phosphate and benzoyl peroxide | 2 | 14 |
| Erythromycin and benzoyl peroxide | 2 | 3 |
| Azathioprine | 2 | 19 |
| Metformin hydrochloride | 2 | 79 |
| Budesonide | 2 | 40 |
| Isosorbide dinitrate | 2 | 18 |
| Tetrabenazine | 2 | 12 |
| Tetracaine hydrochloride | 1 | 9 |
| Imiquimod | 1 | 10 |
| Flunisolide | 1 | 3 |
| Clindamycin phosphate | 1 | 31 |
| Desmopressin acetate | 1 | 27 |
| Diclofenac sodium | 1 | 109 |
| Metronidazole | 1 | 68 |
| Sodium sulfacetamide | 1 | 10 |
| Hydrocortisone butyrate | 1 | 6 |
| Brinzolamide | 1 | 6 |
| Ribavirin | 1 | 2 |
| Clindamycin phosphate and tretinoin | 1 | 4 |
| Butalbital and acetaminophen tablets | 1 | 1 |
| Dihydroergotamine mesylate | 1 | 13 |
| Ipratropium bromide | 1 | 23 |
| Ethacrynic acid | 1 | 10 |
| Metyrosine | 1 | 4 |
| Luliconazole | 1 | 2 |
| Carbidopa tablets | 1 | 1 |
| Ipratroprium bromide | 1 | 1 |
| Tolcapone | 1 | 3 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 17 | 21.8% |
| Tablet, extended release | 13 | 16.7% |
| Gel | 11 | 14.1% |
| Capsule, extended release | 10 | 12.8% |
| Cream | 6 | 7.7% |
| Tablet, film coated, extended release | 5 | 6.4% |
| Kit | 3 | 3.8% |
| Solution | 2 | 2.6% |
| Spray, metered | 2 | 2.6% |
| Solution/ drops | 1 | 1.3% |
| Aerosol, foam | 1 | 1.3% |
| Lotion | 1 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Bupropion Hydrobromide | 68682-582 | Tablet, extended release | Authorized generics (NDA) | June 29, 2026 |
| Bupropion Hydrobromide | 68682-581 | Tablet, extended release | Authorized generics (NDA) | June 29, 2026 |
| Bupropion Hydrobromide | 68682-580 | Tablet, extended release | Authorized generics (NDA) | June 29, 2026 |
| Ipratropium Bromide | 68682-399 | Spray, metered | Generic drugs (ANDA) | June 1, 2025 |
| Ipratroprium Bromide | 68682-398 | Spray, metered | Generic drugs (ANDA) | June 1, 2025 |
| Flunisolide | 68682-344 | Solution | Generic drugs (ANDA) | June 1, 2025 |
| Desmopressin Acetate | 68682-342 | Solution | Generic drugs (ANDA) | June 1, 2025 |
| Tretinoin | 68682-515 | Gel | Authorized generics (NDA) | December 1, 2023 |
| Clindamycin Phosphate and Benzoyl Peroxide | 68682-133 | Gel | Authorized generics (NDA) | October 2, 2023 |
| Metronidazole | 68682-202 | Cream | New drug applications (NDA) | August 1, 2023 |
| Azathioprine | 68682-241 | Tablet | Generic drugs (ANDA) | February 4, 2023 |
| Azathioprine | 68682-231 | Tablet | Generic drugs (ANDA) | February 4, 2023 |
| Budesonide | 68682-658 | Aerosol, foam | New drug applications (NDA) | July 15, 2022 |
| Brinzolamide | 68682-464 | Suspension/ drops | Generic drugs (ANDA) | August 25, 2021 |
| Metyrosine | 68682-310 | Capsule | Authorized generics (NDA) | September 7, 2020 |
| Clindamycin Phosphate 1.2% and Tretinoin 0.025% | 68682-300 | Gel | Authorized generics (NDA) | August 4, 2020 |
| Isosorbide Dinitrate | 68682-193 | Tablet | New drug applications (NDA) | March 2, 2020 |
| Isosorbide Dinitrate | 68682-192 | Tablet | New drug applications (NDA) | March 2, 2020 |
| Diltiazem Hydrochloride | 68682-704 | Tablet, extended release | Authorized generics (NDA) | October 1, 2019 |
| Tetracaine Hydrochloride | 68682-920 | Solution/ drops | New drug applications (NDA) | June 27, 2019 |
| Pimecrolimus | 68682-112 | Cream | Authorized generics (NDA) | November 26, 2018 |
| Pimecrolimus | 68682-111 | Cream | Authorized generics (NDA) | November 26, 2018 |
| Pimecrolimus | 68682-110 | Cream | Authorized generics (NDA) | November 26, 2018 |
| Budesonide | 68682-309 | Tablet, extended release | Authorized generics (NDA) | July 10, 2018 |
| Clindamycin Phosphate and Benzoyl Peroxide | 68682-132 | Gel | Authorized generics (NDA) | July 2, 2018 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.